8-K: Microbot Medical Nears LIBERTY Full Release, Presents at Roth

Microbot Medical Inc. announced its participation in the Roth Annual Growth Conference and confirmed its LIBERTY Endovascular Robotic System is on target for full market release in April 2026.

Summary

• Microbot Medical Inc. will participate in the Roth Annual Growth Conference, held from March 22-24, 2026, in Laguna Niguel, CA.
• Harel Gadot, CEO, President & Chairman, will present live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23, 2026.
• The presentation will highlight recent achievements and how the LIBERTY system addresses critical unmet healthcare needs, including physician safety and staffing issues.
• A live webcast of the presentation will be accessible via the Investors section of the company's website.
• Mr. Gadot will also conduct pre-scheduled one-on-one meetings with growth-oriented institutional investors on March 23, 2026.
• The company's LIBERTY Endovascular Robotic System is on target for its full market release in April 2026, following a successful limited market release that commenced in late 2025.
• LIBERTY is described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
• The full market release aims to deepen market adoption and will be showcased at the Society of Interventional Radiology (SIR) conference in April 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, indicating successful progress in commercialization and strategic investor engagement for a unique, FDA-cleared medical device.

Positives

• Participation in the Roth Annual Growth Conference provides a platform to showcase commercial momentum and growth story to a diverse investor audience.
• The limited market release of the LIBERTY system has shown ongoing progress and success, driven by multi-site customer traction and procedural diversity.
• The full market release of the LIBERTY system is on target for April 2026, indicating successful execution of the commercialization strategy.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, highlighting a unique market position.
• The system is designed to address critical unmet healthcare needs, including physician safety and staffing issues, and aims to reduce radiation exposure and physical strain.

Risks

• Market conditions may impact the company's performance.
• Risks are inherent in the commercialization of the LIBERTY Endovascular Robotic System.
• Development of future versions of or applications for the system carries inherent risks.
• Uncertainty exists in the results of regulatory pathways and regulatory approvals.
• Political, social, and geopolitical conditions, particularly changes at the FDA, could create uncertainty.
• Announcements of tariffs on imports into the U.S. may affect operations.
• Disruptions from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries pose risks.
• Maintenance of intellectual property rights is crucial and subject to potential challenges.

Future Outlook

The company anticipates continued commercial momentum and growth following the successful limited market release and the upcoming full market release of the LIBERTY Endovascular Robotic System in April 2026. They aim to deepen market adoption and introduce their differentiated growth story to a diverse audience.

Management Comments

• "We believe the ongoing progress and success of our limited market release, driven by multi-site customer traction and procedural diversity, has validated our strategy to support the full market release, which is on target for next month."
• "We believe the Roth conference is an ideal stage to showcase this commercial momentum and introduce our differentiated growth story to a diverse audience, to support our current position and future growth."

Industry Context

StockSavvy.ai notes that Microbot Medical's participation in a prominent growth conference and the impending full market release of its LIBERTY system align with the broader trend of increasing adoption of robotic assistance in medical procedures, particularly in endovascular interventions. The focus on physician safety and addressing staffing issues positions LIBERTY to capitalize on critical needs within the healthcare industry, where efficiency and reduced physical strain for medical professionals are becoming increasingly important.

Comparison to Industry Standards

• LIBERTY is highlighted as the "only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures," suggesting a unique market position compared to other robotic systems that may not have this specific combination of features or regulatory clearance for this application.
• The system aims to reduce radiation exposure and physical strain, which are common challenges in traditional endovascular procedures, potentially offering a superior solution compared to existing manual or less advanced robotic methods.

Stakeholder Impact

• Shareholders: Potential for increased investor interest and share price appreciation due to successful product commercialization and investor outreach.
• Customers (Healthcare Providers): Access to an innovative, FDA-cleared robotic system designed to improve physician safety, address staffing issues, and enhance precision in endovascular procedures.
• Patients: Potential for improved outcomes and safety in peripheral endovascular procedures due to the precision and reduced radiation exposure offered by the LIBERTY system.
• Employees: Positive impact from successful product launch and company growth, potentially leading to job security and expansion.

Next Steps

• Harel Gadot to present at the Roth Annual Growth Conference on March 23, 2026.
• Harel Gadot to hold one-on-one meetings with institutional investors on March 23, 2026.
• Full market release of the LIBERTY Endovascular Robotic System in April 2026.
• Showcase LIBERTY at the Society of Interventional Radiology (SIR) conference in April 2026.

Key Dates

Recommendation

The company is demonstrating clear commercial momentum with its FDA-cleared LIBERTY system, validated by a successful limited market release and an imminent full market launch. The product addresses critical unmet needs in healthcare, and the company is actively engaging with institutional investors to highlight its differentiated growth story. This combination of product uniqueness, market readiness, and strategic investor outreach presents a compelling investment opportunity.

Keywords

Microbot Medical, MBOT, LIBERTY Endovascular Robotic System, Robotic Surgery, Medical Device, FDA Cleared, Endovascular Procedures, Healthcare Technology, Roth Conference, Investor Relations, Commercialization, Peripheral Procedures